Gilead Sciences (GILD) Net Equity Issued and Repurchased (2009 - 2026)

Gilead Sciences (GILD) has reported Net Equity Issued and Repurchased for 18 consecutive years, with $9.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Equity Issued and Repurchased fell 66.67% year-over-year to $9.0 million; the trailing twelve-month figure through Jun 2026 stood at $304.0 million (down 44.73% YoY), and the FY2025 full-year result was $408.0 million, down 3.32% from the prior year.
• Net Equity Issued and Repurchased retreated to $9.0 million in Q2 2026 per GILD's latest filing, from $166.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $252.0 million in Q1 2025 and bottomed at $3.0 million in Q2 2022.
• Historically, Net Equity Issued and Repurchased has averaged $85.9 million across 5 years, with a median of $88.5 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Net Equity Issued and Repurchased jumped 1366.67% in 2022, then plunged 85.23% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at $176.0 million in 2022, then slumped by 85.23% to $26.0 million in 2023, then soared by 565.38% to $173.0 million in 2024, then slumped by 81.5% to $32.0 million in 2025, then slumped by 71.88% to $9.0 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $9.0 million, $166.0 million, and $32.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.